This website uses cookies
Read our Privacy policy and Terms of use for more information.
CV
+3

Apr 15, 2026
•
16 min read
Muscle damage. Memory loss. Cancer. Diabetes. Four fears, one physician, and what the evidence actually shows.

CV
+3

Apr 11, 2026
•
12 min read
The receptor story that explains 40 years of cardiovascular outcomes data — and why the pleiotropic hypothesis was never the whole story.

GLP1
+2

Apr 8, 2026
•
14 min read
Six interventions. One thesis about time. What I take every morning and why the evidence earned each one a place in the rotation.

CV
+2

Apr 4, 2026
•
16 min read
Here's what the evidence actually says — and why I stopped waiting for symptoms before acting on it.

CV
+2

Apr 1, 2026
•
17 min read
New guidelines. New trials. The same conclusion. The deniers didn't get the memo.

GLP1
+3

Mar 27, 2026
•
15 min read
It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.

Michael Albert, MD. Board-certified obesity medicine physician. Chief Medical Officer, Vineyard.
Get the evidence in your inbox
Free, twice a week. Every number sourced to the trial. Unsubscribe anytime.
© 2026 Michael Albert MD LLC · Not medical advice. Dr. Albert is Chief Medical Officer of Vineyard.